Back to Search
Start Over
Green propolis increases myeloid suppressor cells and CD4 + Foxp3 + cells and reduces Th2 inflammation in the lungs after allergen exposure.
- Source :
-
Journal of ethnopharmacology [J Ethnopharmacol] 2020 Apr 24; Vol. 252, pp. 112496. Date of Electronic Publication: 2019 Dec 21. - Publication Year :
- 2020
-
Abstract
- Ethnopharmacological Relevance: Propolis is a natural product produced by honeybees used as a medicine at least to 300 BC. In the last decades, several studies showed biological and pharmacological properties of propolis, witch scientifically explains the empirical use for centuries. The anti-inflammatory activity of propolis with the purpose to reduce Th2 inflammation has been evaluated in allergic asthma. However, it remains to be determined how propolis negatively regulates the immune response after allergen re-exposure.<br />Aim of the Study: We hypothesized that the anti-inflammatory activity of propolis is dependent on the induction of myeloid derived suppressor cells (MDSC) and regulatory T cells.<br />Materials and Methods: To assess this hypothesis, we used an ovalbumin-induced asthma model to evaluate the effect of EPP-AF® dry extract from Brazilian green propolis.<br />Results: Propolis treatment decreased pulmonary inflammation and mucus production as well as eosinophils and IL-5 in the broncoalveolar lavage. Propolis enhanced also in vitro differentiation and in vivo frequency of lung MDSC and CD4 <superscript>+</superscript> Foxp3 <superscript>+</superscript> regulatory T cells.<br />Conclusions: Together these results confirm the immunomodulatory potential of propolis during sensitization and challenge with allergen. In addition, the collecting findings show, for the first time, that propolis increases the frequency of MDSC and CD4 <superscript>+</superscript> Foxp3 <superscript>+</superscript> regulatory T cells in the lungs, and suggest that it could be use as target for development of new immunotherapy or adjuvant immunotherapy for asthma.<br />Competing Interests: Declaration of competing interest The authors have no conflicts of interest to disclose.<br /> (Copyright © 2019. Published by Elsevier B.V.)
- Subjects :
- Allergens
Animals
Anti-Inflammatory Agents pharmacology
Asthma chemically induced
Asthma immunology
Bronchoalveolar Lavage Fluid cytology
Bronchoalveolar Lavage Fluid immunology
Cell Differentiation drug effects
Female
Immunologic Factors pharmacology
Immunotherapy
Interleukin-13 genetics
Interleukin-13 immunology
Interleukin-5 immunology
Lung drug effects
Lung immunology
Mice, Inbred C57BL
Myeloid-Derived Suppressor Cells immunology
Ovalbumin
Propolis pharmacology
T-Lymphocytes, Regulatory immunology
Th2 Cells drug effects
Th2 Cells immunology
Anti-Inflammatory Agents therapeutic use
Asthma drug therapy
Immunologic Factors therapeutic use
Myeloid-Derived Suppressor Cells drug effects
Propolis therapeutic use
T-Lymphocytes, Regulatory drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1872-7573
- Volume :
- 252
- Database :
- MEDLINE
- Journal :
- Journal of ethnopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 31870795
- Full Text :
- https://doi.org/10.1016/j.jep.2019.112496